Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

ve Growth Factor (NGF), a novel target for pain, began a dose ranging study in osteoarthritis of the knee. Trial results are expected during the first half of 2010. A Phase 1 study of REGN475 in healthy volunteers is also continuing, and Phase 1 studies are in progress with REGN88, an antibody to the interleukin-6 receptor (IL-6R) that is being evaluated in rheumatoid arthritis, and REGN421, an antibody to Delta-like ligand-4 (Dll4) that is being studied in patients with advanced malignancies. REGN475, REGN88, and REGN421 are fully human monoclonal antibodies generated by Regeneron using the VelocImmune® technology and developed within the Company's human antibody collaboration with sanofi-aventis. Regeneron and sanofi-aventis expect to enter two more human monoclonal antibodies into clinical development this year and to advance an average of two to three into clinical development each year thereafter over the next several years.

Financial Results

Revenues

Total revenues increased to $117.5 million in the third quarter of 2009 from $65.6 million in the same quarter of 2008 and increased to $282.5 million for the first nine months of 2009 from $182.6 million for the same period of 2008. The Company's revenue was comprised of contract research and development revenue, a 2009 research progress payment, technology licensing revenue, and net product sales.

Contract Research and Development Revenue

Contract research and development revenue relates primarily to the Company's aflibercept and antibody collaborations with sanofi-aventis and the Company's VEGF Trap-Eye collaboration with Bayer HealthCare. Contract research and development revenue for the three and nine months ended September 30, 2009 and 2008 consisted of the following:

                                       Three months ended  Nine months ended
                                          September 30,      S
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... and VANCOUVER , July 30, 2015 ... today that it will report its second quarter 2015 ... will host a conference call and live webcast at ... financial results, clinical development programs and a general corporate ... on to the Investor Relations page of the OncoGenex ...
(Date:7/30/2015)... FALLS, Ohio , July 30, 2015  Cleveland ... his OMTEC® 2015 keynote address last month that industry ... models in order to gain the efficiencies—and develop the ... Dr. Barsoum,s comments were preceded by ... avid entrepreneur and OMTEC moderator, who stressed that industry ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... today announced the national availability and receipt of ... pain medication monitoring program offering the industry,s highest ... and identify potential negative drug interactions before they ... concerns of prescription pain medication abuse by using ...
... ISIS ), the leader in antisense therapeutics, today ... Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June ... in Rancho Palos Verdes, CA. A live audio ... & Media" section of the Company,s Web site, www.isispharm.com ...
Cached Medicine Technology:PeaceHealth Laboratories' New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse 2
(Date:7/31/2015)... ... ... a reputable source of authentic USA vs. Australia tickets at Ford Field in ... in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup by ... awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the ... Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is ... providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... McLean, VA (PRWEB) , ... July 31, 2015 , ... ... solution at OSEHRA 2015. , What is HITaaS? Health IT as a Service (HITaaS) ... (IaaS) and software as a service (SaaS). , HITaaS manages all aspects ...
(Date:7/31/2015)... ... ... Physical therapy for knee osteoarthritis is an important part of knee ... patient from doing what they want or need to do. The patient may have trouble ... The patient's exercise regime may be limited by the pain in their knee. When a ...
(Date:7/31/2015)... McMinnville, OR (PRWEB) , ... July 31, 2015 , ... ... the Granary District Stage Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – ... is an exciting and important day for the entire community as the culmination of ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3
... 2010 Elsevier, a world-leading publisher of scientific, ... announced the launch of SciVerse, an innovative platform ... the scientific community to collaborate on the development ... committed to releasing the APIs (application programming interfaces) ...
... French . The medicinal use of cannabis has ... large for many years as an alternative to standard pharmaceutical ... may have unwanted side effects. A new study by McGill ... that cannabis may offer relief to patients suffering from chronic ...
... , SUNDAY, Aug. 29 (HealthDay News) -- Having a particular ... risk of getting migraines, new research shows. While migraines ... specific genes has proven difficult, the researchers said. The ... genetic variant associated with a heightened risk for the most ...
... people suffering chronic pain, smoked cannabis reduces pain, ... research published in CMAJ (Canadian Medical Association Journal) ... who suffer from chronic neuropathic pain due to ... few treatment options. These options include opioids, anticonvulsants, ...
... Many children are being put at risk by parents over-use ... and colds, says a study from Australia to be presented ... today (Monday 30 August). The researchers, led ... South Wales, say that dosing errors and inappropriate use of ...
... FRIDAY, Aug. 27 (HealthDay News) -- While attention-deficit hyperactivity disorder ... there is a cluster of kids and adults who successfully ... privileges in school. "People who want to fake ADHD ... on a number of standard clinical instruments that are used ...
Cached Medicine News:Health News:Elsevier introduces SciVerse, an innovative platform for accelerating science 2Health News:Research demonstrates benefits of medical cannabis as a treatment for chronic pain 2Health News:New Migraine Gene Discovered 2Health News:New Migraine Gene Discovered 3Health News:Smoked cannabis reduces chronic pain 2Health News:Widespread parental misuse of medicines puts children at risk 2Health News:Widespread parental misuse of medicines puts children at risk 3Health News:Some Fake ADHD to Get Meds, Special Treatment 2Health News:Some Fake ADHD to Get Meds, Special Treatment 3
The Leica M500 OH3 is an advanced surgical microscope used by neurosurgeons. It is a smart system combining the best optical performance available on the market with an innovative and unique stand....
Surgical Loupes...
... MAGNETOM Allegra is the ultimate brain ... been optimized for best image quality ... all in a highly compact design. ... diagnosing stroke, epilepsy, tumor and multiple ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: